← Research library
TransMedics Group
- Rating
- Price at publication
- $113.36
- Target price
- $175–$190
- Stated upside
- 54%–68%
- Published
- 14 April 2026
Thesis
TransMedics is a rapidly expanding medical technology company changing organ transplantation with its Organ Care System.
Key risks
- 01Delays in FDA or international approvals
- 02Uncertain clinical trial outcomes
- 03New organ-preservation technologies from competitors
Price, target and upside are as stated in the report on 14 April 2026, not updated since.
Full report
Open in a new tab ↗Educational research. This report reflects the views of its student author as of 14 April 2026. It is not investment advice or a recommendation to buy or sell any security. Full disclaimer.